Please login to the form below

Not currently logged in
Email:
Password:

MHLW

This page shows the latest MHLW news and features for those working in and with pharma, biotech and healthcare.

MSD’s Keytruda wins bladder cancer indication in Japan

MSD’s Keytruda wins bladder cancer indication in Japan

Bladder cancer patients living in Japan can now access Merck Sharp and Dohme’s (MSD) Keytruda (pembrolizumab) following a green light from the Japanese Ministry of Health, Labour and Welfare (MHLW).

Latest news

  • Ono faces steep price cut for Opdivo in Japan Ono faces steep price cut for Opdivo in Japan

    The MHLW committee has accelerated that process by activating an emergency provision that allows earlier cuts for big-selling drugs – making 100bn to 150bn yen a year – and which exceed company

  • Japanese approvals for GSK, AZ and Bayer Japanese approvals for GSK, AZ and Bayer

    Japanese approvals for GSK, AZ and Bayer. MHLW gives Nucala, Tagrisso and Xofigo the green light. ... The Ministry of Health, Labour and Welfare (MHLW) gave the go-ahead to interleukin-5 inhibitor Nucala (mepolizumab) as a treatment for bronchial asthma

  • Takeda's once-weekly DPP-4 inhibitor cleared in first market Takeda's once-weekly DPP-4 inhibitor cleared in first market

    GlaxoSmithKline (GSK) has been given the go-ahead by the MHLW to market its long-acting muscarinic antagonist (LAMA) Encruse (umeclidinium) for chronic obstructive pulmonary disease (COPD). ... Amgen/Astellas' PCSK9-targeting antibody Repatha (evolocumab)

  • Novartis' Japanese subsidiary threatened with suspension Novartis' Japanese subsidiary threatened with suspension

    The company is staying tight-lipped about the reasons for the unusual action by the Ministry Of Health, Labour and Welfare (MHLW), although it has confirmed it has received a

  • Japan first to approve Novartis psoriasis drug Cosentyx Japan first to approve Novartis psoriasis drug Cosentyx

    The Japanese Ministry of Health, Labour and Welfare (MHLW) cleared Cosentyx (secukinumab) as a second-line therapy after non-biologic systemic treatment for psoriasis or psoriatic arthritis has failed.

More from news
Approximately 1 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    Ministry of Health, Labour and Welfare (MHLW) data revealed that the largest single cause of death was cancer, followed by stroke and heart disease. ... Additionally, if sales of a new drug are greater than estimated by the manufacturer, then its price

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics